DURHAM, N.C.--(BUSINESS WIRE)--GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback